StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Free Report) from a hold rating to a buy rating in a research report released on Thursday morning.
Separately, Truist Financial reduced their price objective on Compugen from $5.00 to $4.00 and set a buy rating for the company in a report on Tuesday, May 21st.
View Our Latest Analysis on Compugen
Compugen Price Performance
Compugen (NASDAQ:CGEN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.06. The company had revenue of $6.70 million during the quarter, compared to the consensus estimate of $2.68 million. During the same period in the prior year, the firm posted ($0.11) EPS. Research analysts expect that Compugen will post 0.05 EPS for the current fiscal year.
Hedge Funds Weigh In On Compugen
Large investors have recently modified their holdings of the business. Heron Bay Capital Management bought a new position in shares of Compugen in the first quarter worth $32,000. Secure Asset Management LLC purchased a new stake in Compugen during the 2nd quarter worth about $69,000. Squarepoint Ops LLC lifted its holdings in Compugen by 23.4% during the 2nd quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 16,253 shares in the last quarter. Rothschild Investment LLC bought a new position in Compugen in the 2nd quarter worth about $380,000. Finally, ARK Investment Management LLC grew its holdings in Compugen by 4.7% during the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock valued at $1,850,000 after buying an additional 48,979 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company’s stock.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
See Also
- Five stocks we like better than Compugen
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- This Small Cap Wealth Management Stock Could Provide Big Returns
- How to Buy Cheap Stocks Step by Step
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Consumer Discretionary Stocks Explained
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.